scholarly journals Efficacy and safety of Xa factor antagonists in patients with nonvalvular atrial fibrillation

2021 ◽  
Vol 30 (2) ◽  
pp. 59-66
Author(s):  
V.N. Drozdovа ◽  
E.K. Kochetkovaа
Keyword(s):  
Atrial Fibrillation ◽  
Adverse Reactions ◽  
Factor Xa ◽  
Current Data ◽  
Individual Characteristics ◽  
Thromboembolic Events ◽  
Efficacy And Safety ◽  
Nonvalvular Atrial Fibrillation ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

Factor Xa antagonists are used increasingly frequently for prevention and treatment of venous thromboembolic events and for prevention of stroke and systemic emboli in patients with non-valvular atrial fibrillation. Individual characteristics of patient, a need in prolonged or life-long treatment, concomitant diseases, the use of other drugs interacting with anticoagulants increase the risk of side effects of anticoagulation. We analyzed the current data on the efficacy and safety of Xa factor antagonists, as well as the features of their use in the event of adverse reactions, particularly bleedings. The possibilities of monitoring the efficacy and safety of treatment with these drugs were evaluated.

scholarly journals Edoxaban in patients with atrial fibrillation

2016 ◽  
Vol 11 (3) ◽  
pp. 81-90 ◽  
Author(s):  
Alon Eisen ◽  
Christian T. Ruff
Keyword(s):  
Atrial Fibrillation ◽  
Factor Xa ◽  
Phase Iii ◽  
Factor Xa Inhibitor ◽  
Efficacy And Safety ◽  
Direct Factor ◽  
Nonvalvular Atrial Fibrillation ◽  
Preclinical Development ◽  
Phase Iii Trial ◽  
Prevention And Treatment

Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.

scholarly journals Recurrence of Upper Extremity Deep Vein Thrombosis Secondary to COVID-19

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 878
Author(s):  
Yesha H. Parekh ◽  
Nicole J. Altomare ◽  
Erin P. McDonnell ◽  
Martin J. Blaser ◽  
Payal D. Parikh
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Extremity ◽  
Upper Extremity ◽  
Thromboembolic Events ◽  
Vein Thrombosis ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Deep Vein

Infection with SARS-CoV-2 leading to COVID-19 induces hyperinflammatory and hypercoagulable states, resulting in arterial and venous thromboembolic events. Deep vein thrombosis (DVT) has been well reported in COVID-19 patients. While most DVTs occur in a lower extremity, involvement of the upper extremity is uncommon. In this report, we describe the first reported patient with an upper extremity DVT recurrence secondary to COVID-19 infection.

Sign in / Sign up

Export Citation Format

Share Document